Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has announced the issuance of 314,843 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This move is part of the company’s ongoing efforts to maintain transparency and adhere to regulatory requirements, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases.
Average Trading Volume: 1,056,012
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.68M
See more data about IMC stock on TipRanks’ Stock Analysis page.